-

ROSEN, A TOP RANKED LAW FIRM, Announces Investigation of Securities Claims Against Cypress Semiconductor Corporation – CY

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Cypress Semiconductor Corporation (NASDAQ: CY) resulting from allegations that Cypress may have issued materially misleading business information to the investing public.

On March 3, 2020, the Food and Drug Administration (“FDA”) issued a news release “informing patients, health care providers and manufacturers about a set of cybersecurity vulnerabilities, referred to as ‘SweynTooth,’ that—if exploited—may introduce risks for certain medical devices.” The FDA named Cypress as one “of several manufacturers that are affected by these vulnerabilities.”

On this news, Cypress’s stock price fell sharply over the following trading sessions.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Cypress investors. If you purchased Cypress securities, please visit the firm’s website at http://www.rosenlegal.com/cases-register-1819.html to join the class action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

Rosen Law Firm

NASDAQ:CY

Release Versions

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

Social Media Profiles
More News From Rosen Law Firm

Rosen Law Firm Urges Super Micro Computer, Inc. (NASDAQ: SMCI) Stockholders to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Super Micro Computer, Inc. (NASDAQ: SMCI) between April 30, 2024 and March 19, 2026. Super Micro describes itself as a “technology company which designs, develops, and manufactures high-performance server and storage systems, primarily for artificial intelligence ('AI'), data center, and cloud solutions customers.” For more information, submit a...

Rosen Law Firm Encourages ImmunityBio, Inc. Investors to Inquire About Securities Class Action Investigation – IBRX

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ImmunityBio, Inc. (NASDAQ: IBRX) resulting from allegations that ImmunityBio, Inc. may have issued materially misleading business information to the investing public. So What: If you purchased ImmunityBio, Inc. securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc...

Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026. Atara describes itself as a company that “develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the U.S. and the United Kingdom.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 8...
Back to Newsroom